Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Merck
Medtronic
Colorcon
Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PAROXETINE HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Paroxetine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000368 Treatment of Panic Disorder: Long Term Strategies Completed National Institute of Mental Health (NIMH) Phase 3 1999-02-01 Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00000368 Treatment of Panic Disorder: Long Term Strategies Completed New York State Psychiatric Institute Phase 3 1999-02-01 Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
NCT00012558 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Completed National Institute of Mental Health (NIMH) N/A 1998-09-01 A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies.
NCT00018733 Biological Aspects of Depression and Antidepressant Drugs Completed VA Office of Research and Development N/A 1996-09-01 This study will be measuring changes in depressive symptoms over a 7 week time period. Double-blind placebo controlled trial using the pharmacologic agents Paroxetine or Desipramine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Paroxetine Hydrochloride

Condition Name

Condition Name for Paroxetine Hydrochloride
Intervention Trials
Depression 25
Major Depressive Disorder 24
Depressive Disorder 19
Panic Disorder 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Paroxetine Hydrochloride
Intervention Trials
Depression 90
Depressive Disorder 78
Disease 77
Depressive Disorder, Major 52
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Paroxetine Hydrochloride

Trials by Country

Trials by Country for Paroxetine Hydrochloride
Location Trials
United States 482
Canada 41
Germany 30
China 27
Japan 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Paroxetine Hydrochloride
Location Trials
New York 34
California 28
Pennsylvania 27
Florida 23
Texas 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Paroxetine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Paroxetine Hydrochloride
Clinical Trial Phase Trials
Phase 4 72
Phase 3 53
Phase 2/Phase 3 4
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Paroxetine Hydrochloride
Clinical Trial Phase Trials
Completed 168
Terminated 17
Recruiting 16
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Paroxetine Hydrochloride

Sponsor Name

Sponsor Name for Paroxetine Hydrochloride
Sponsor Trials
GlaxoSmithKline 52
National Institute of Mental Health (NIMH) 16
Sanofi 12
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Paroxetine Hydrochloride
Sponsor Trials
Other 184
Industry 129
NIH 24
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKinsey
Medtronic
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.